| abstract |
An inhibitor of complement factor D comprising a compound of formula I or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is aryl, heteroaryl or heterocycle (R 32 ) Compounds, methods of use and processes are provided. Inhibitors described herein target Factor D, inhibit or regulate the complement cascade at early critical points in the alternative complement pathway, and modulate Factor D pathway that modulates the classical and lectin complement pathways. Reduce capacity. Inhibitors of factor D described herein reduce complement overactivation associated with several autoimmune diseases, inflammatory and neurodegenerative diseases, and ischemia-reperfusion injury and cancer It is possible. [Selection figure] None |